Orrin Hatch: “my staff just attended a non-embargoed briefing conducted by the Federal Trade Commission. It is our understanding that…”

“my staff just attended a non-embargoed briefing conducted by the Federal Trade Commission. It is our understanding that tomorrow the FTC will transmit to the Congress and the American people a copy of its comprehensive study of the pharmaceutical industry with respect to litigation involving the two major components of the pending legislation: first, the report examined the use and abuses of the statutory 30-month stay. Second, the report examines how the 180-day marketing exclusivity rule has been the source of collusive arrangements between pioneer and generic firms. I will be very interested to study the full report when it released tomorrow morning. Let me say this tonight. First, I want to commend Chairman Muris and the other FTC Commissioners for undertaking this important study. I would also like to acknowledge the efforts of the FTC staff including, Maryann Kane, Mike Wroblenski and Sarah Browers for their work on this report. It is my understanding that the key recommendations contained in the report are somewhat at odds with the legislation on the floor.”